• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21597 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: Healthcare systems in the future: what priorities guide innovation?]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Implantable devices for left atrial appendage closure. Monitoring study]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Biodegradable stents for the treatment of benign esophageal strictures. Monitoring study]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dosing of a new generation anti-seizure panel by LC-MS/MS]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Biomarkers in Parkinson's Disease]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Liposuction for the removal of subcutaneous (large) lipomas]
2024     Scottish Health Technologies Group (SHTG) Green theatres
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2024     Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2024     Agency for Care Effectiveness (ACE) Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2024     Agency for Care Effectiveness (ACE) Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
2024     NIHR Health Services and Delivery Research programme ‘Why are we stuck in hospital?’ Barriers to people with learning disabilities/autistic people leaving ‘long-stay’ hospital: a mixed methods study
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Strategies used for childhood chronic functional constipation: the SUCCESS evidence synthesis
2024     NIHR Health Technology Assessment programme Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
2024     NIHR Health Technology Assessment programme Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial
2024     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of an adapted intervention for preschoolers with moderate to severe intellectual disabilities displaying behaviours that challenge: the EPICC-ID RCT
2024     NIHR Health Technology Assessment programme Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of chronic obstructive pulmonary disease in Quebec from 2016 to 2022 - healthcare Indicator results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     NIHR Health Services and Delivery Research programme Conceptual framework on barriers and facilitators to implementing perinatal mental health care and treatment for women: the MATRIx evidence synthesis
2024     NIHR Health Services and Delivery Research programme Factors within the clinical encounter that impact upon risk assessment within child and adolescent mental health services: a rapid realist synthesis
2024     NIHR Public Health Research (PHR) programme Support needs of survivors of violence against women in urban India: a prospective analysis of client records
2024     Health Information and Quality Authority (HIQA) Advances in the development of clinical practice guidance - scoping review
2024     Health Information and Quality Authority (HIQA) Enhanced inactivated influenza vaccines for over 65s: protocol for a health technology assessment
2024     Health Information and Quality Authority (HIQA) Herpes zoster (shingles) vaccination: protocol for a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Belgian Health Care Knowledge Centre (KCE) Use of diagnostic immunohistochemistry and electron microscopy tests in Belgium (Study 2021-01)
2024     Belgian Health Care Knowledge Centre (KCE) Large-scale lung cancer screening (Study 2021-02)
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell counting in the preoperative evaluation of cataract surgery (Study 2023-12)
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation for the management of resistant hypertension]
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic and clinical utility of impulse oscillometry for use in patients with difficulty performing spirometry]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm